Rebranding Signals Strategic Shift Beyond
Biopharmaceuticals, Highlights Commitment to Technology, Artificial
Intelligence and Shareholder Value
WEXFORD,
Pa., Jan. 30, 2025 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company focused on pioneering cell
therapy platforms for cancer, autoimmune, and infectious diseases,
is excited to announce its rebranding to COEPTIS, marking a
transformative shift in its business strategy. This pivotal change
reflects our commitment to expanding beyond biopharmaceuticals and
embracing diverse growth opportunities in technology-driven
sectors.
With the establishment of our new Technology Division, COEPTIS aims
to enhance operational capabilities and maximize shareholder value.
Central to this initiative was the recent acquisition of the
NexGenAI Affiliates Network platform, a groundbreaking AI-powered
marketing solution. This acquisition aligns seamlessly with
COEPTIS's mission to innovate in highly regulated industries,
revolutionizing marketing strategies and operational
efficiencies.
By integrating NexGenAI's advanced tools, COEPTIS empowers
companies to tackle marketing challenges in competitive landscapes
with AI-driven precision and efficiency. Building on this
foundation, our Technology Division is expanding its automation
capabilities and developing AI agents to optimize workflows and
drive operational efficiency through intelligent automation.
Dave Mehalick, President and CEO
of Coeptis, stated, "This strategic move not only reinforces our
commitment to innovation but also strengthens our efforts to expand
into revenue-generating, cash flow-positive business units. By
leveraging cutting-edge technologies, we are positioning COEPTIS as
a self-sustaining entity, creating a robust foundation for
long-term growth and profitability."
"NexGenAI Affiliates Network stands apart as a trailblazer in
delivering practical, transformative AI solutions tailored for
real-world business needs. Unlike traditional AI firms focused on
narrow applications or theoretical advancements, Coeptis
Technologies leverages a proprietary suite of advanced
technologies; including AI-driven marketing software, robotic
process automation (RPA), and actionable data analytics—to empower
businesses across diverse sectors. Our platform is designed not
just to automate processes, but to enhance communication
strategies, optimize campaigns, and drive sustainable growth and we
remain committed to responsible innovation harnessing the power of
technology to create meaningful impact and deliver tangible value."
added Mr. Mehalick.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics, Inc., Coeptis
Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP
Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical
and technology company focused on developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis aims to advance treatment paradigms and improve patient
outcomes through its cutting-edge research and development
efforts.
The Company's therapeutic portfolio is underscored by assets
licensed from Deverra Therapeutics, which include an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Coeptis is also
developing a universal, multi-antigen CAR technology licensed from
the University of Pittsburgh
(SNAP-CAR), alongside GEAR cell therapy and companion diagnostic
platforms in collaboration with VyGen-Bio and distinguished medical
researchers at the Karolinska
Institute.
Building on its core competencies, Coeptis has recently
established a Technology Division, which focuses on enhancing
operational capabilities through advanced technologies. This
division features AI-powered marketing software and robotic process
automation tools acquired from NexGenAI Solutions Group, designed
to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA,
Coeptis is dedicated to advancing its mission within the regulatory
framework set forth by the FDA, ensuring that all activities align
with the highest standards of compliance and patient care. For more
information on Coeptis, visit https://coeptistx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the inability to recognize the anticipated
benefits of the Deverra licensed assets, which may be affected by,
among other things, competition, the ability of the Company to grow
and manage growth economically and hire and retain key employees;
(3) the risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (4) costs related to ongoing asset
development including the Deverra licensed assets and pursuing the
contemplated asset development paths; (5) changes in applicable
laws or regulations; (6) the possibility that the Company may be
adversely affected by other economic, business, and/or competitive
factors; and (7) the impact of the global COVID-19 pandemic on any
of the foregoing risks and other risks and uncertainties identified
in the Company's filings with the Securities and Exchange
Commission (the "SEC"). The foregoing list of factors is not
exclusive. All forward-looking statements are subject to
significant uncertainties and risks including, but not limited, to
those risks contained or to be contained in reports and other
filings filed by the Company with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings made or to be made
with the SEC, which are available for review at www.sec.gov. We
undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date hereof unless required by applicable laws, regulations, or
rules.
Contacts
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-holdings-becomes-coeptis-embracing-a-future-of-technology-and-innovation-302364358.html
SOURCE Coeptis Therapeutics, Inc.
